Clinical trials

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Status: Not yet recruiting

A Clinical Trial to Assess the Pharmacokinetics, Safety, and Food Effect of AD-230 in Healthy Adults

A clinical trial to assess the pharmacokinetics, safety, and food effect of AD-230 in healthy adults

Participants needed: 24

Trial details

Phase: Phase 1Age: 19-64Biological sex: AllType: InterventionalSponsor: Addpharma Inc.Updated: Jun 1, 2026Locations: 1

Eligibility criteria

Body mass index (BMI) between 18.5 kg/m2 and 29.9 kg/m2 at the time of screening... [+1]

Participation in another clinical study with an investigational drug within the... [+1]

Status: Not yet recruiting

A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C

Participants needed: 60

Trial details

Phase: Phase 1Age: 19-64Biological sex: AllType: InterventionalSponsor: Addpharma Inc.Updated: May 15, 2026Locations: 1

Eligibility criteria

Body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening... [+1]

Participation in another clinical study with an investigational drug within the... [+1]

Status: Not yet recruiting

Determining the Optimal Dose of AD-211 in Patients With Osteoarthritis of the Knee

The purpose of this study is to determine the optimal dose of AD-211 in patients with osteoarthritis of the knee.

Participants needed: 200

Trial details

Phase: Phase 2Age: 19-75Biological sex: AllType: InterventionalSponsor: Addpharma Inc.Updated: Apr 24, 2026

Eligibility criteria

Signed informed consent [+2]

Patients with secondary osteoarthritis of the knee [+1]

Status: Not yet recruiting

A Study to Evaluate the Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232

Participants needed: 50

Trial details

Phase: Phase 1Age: 19+Biological sex: AllType: InterventionalSponsor: Addpharma Inc.Updated: Apr 20, 2026Locations: 1

Eligibility criteria

Body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening... [+1]

Participation in another clinical study with an investigational drug within the... [+1]

Status: Not yet recruiting

A Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults

Participants needed: 52

Trial details

Phase: Phase 1Age: 19-64Biological sex: AllType: InterventionalSponsor: Addpharma Inc.Updated: Apr 13, 2026Locations: 1

Eligibility criteria

- Body mass index (BMI) between 18.5 kg/m2 and 29.9 kg/m2 at the time of screeni... [+1]

Participation in another clinical study with an investigational drug within the... [+1]

Status: Not yet recruiting

A Study to Evaluate the Safety and Pharmacokinetics of AD-118 and AD-1181 in Healthy Adult Subjects

A Study to Evaluate the Safety and Pharmacokinetics of AD-118 and AD-1181 Under Fasted Conditions in Healthy Adult Subjects

Participants needed: 70

Trial details

Phase: Phase 1Age: 19-64Biological sex: AllType: InterventionalSponsor: Addpharma Inc.Updated: Mar 17, 2026Locations: 1

Eligibility criteria

Body weight equal to or greater than 50kg and Body mass index (BMI) between 18.0... [+1]

Participation in another clinical study with an investigational drug within the... [+1]

Status: Recruiting

A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Subjects

A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 Under Fed Conditions in Healthy Adult Male Subjects

Participants needed: 44

Trial details

Phase: Phase 1Age: 19+Biological sex: MaleType: InterventionalSponsor: Addpharma Inc.Updated: Mar 3, 2026Locations: 1

Eligibility criteria

Body weight equal to or greater than 50kg and Body mass index (BMI) between 18.0... [+1]

Participation in another clinical study with an investigational drug within the... [+1]

Status: Not yet recruiting

A Clinical Trial to Assess the Pharmacokinetics and Safety of AD-229 Compared to AD-2291 in Healthy Adults

The study compare and evaluate the safety and pharmacokinetic characteristics between the administration of AD-229 and the administration of AD-2291 in healthy adults.

Participants needed: 28

Trial details

Phase: Phase 1Age: 19+Biological sex: AllType: InterventionalSponsor: Addpharma Inc.Updated: Feb 27, 2026

Eligibility criteria

Body mass index (BMI) between 18.5 kg/m2 and 29.9 kg/m2 at the time of screening... [+1]

Participation in another clinical study with an investigational drug within the... [+1]

Status: Recruiting

Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151'

The study compare and evaluate the safety and pharmacokinetic characteristics of a single dose administration of 'AD-115A' or 'AD-1151' in healthy adults.

Participants needed: 46

Trial details

Phase: Phase 1Age: 19+Biological sex: AllType: InterventionalSponsor: Addpharma Inc.Updated: Feb 11, 2026Locations: 1

Eligibility criteria

The Age equal to or greater than 19 in healthy volunteers at the time of screeni... [+1]

Individuals who have taken drugs that induce (e.g., barbiturates) or inhibit dru... [+1]

Status: Not yet recruiting

A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-231A and AD-231B and AD-231C

To evaluate the pharmacokinetic interactions of AD-231A, AD-231B, and AD-231C in healthy adult volunteers.

Participants needed: 55

Trial details

Phase: Phase 1Age: 19-64Biological sex: AllType: InterventionalSponsor: Addpharma Inc.Updated: Dec 31, 2025Locations: 1

Eligibility criteria

Healthy adult volunteers aged ≥19 and <65 years at the time of the screening vis... [+1]

Participation in another clinical study with an investigational drug within the... [+1]

Status: Not yet recruiting

Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322

To evaluate the pharmacokinetic interactions of AD-2321, AD-2322 in healthy adult volunteers.

Participants needed: 41

Trial details

Phase: Phase 1Age: 19-64Biological sex: AllType: InterventionalSponsor: Addpharma Inc.Updated: Dec 31, 2025Locations: 1

Eligibility criteria

Healthy adult volunteers aged ≥19 and <65 years at the time of the screening vis... [+1]

Participation in another clinical study with an investigational drug within the... [+1]

Status: Not yet recruiting

A Study to Compare to PK Characteristics and Safety Profiles Between AD-117 and AD-117A

Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-117 in healthy subjects.

Participants needed: 60

Trial details

Phase: Phase 1Age: 19+Biological sex: AllType: InterventionalSponsor: Addpharma Inc.Updated: Dec 4, 2025Locations: 1

Eligibility criteria

Body weight equal to or greater than 50kg (Female 45kg) and Body mass index (BMI... [+1]

Participation in another clinical study with an investigational drug within the... [+1]

Status: Not yet recruiting

A Clinical Trial to Evaluate the Safety and the Pharmacokinetics of AD-116 Compared to AD-1161 in Healthy Adult Male Volunteers

The study compare and evaluate the safety and pharmacokinetic characteristics between the administration of AD-116 and the administration of AD-1161 in healthy adult male volunteers

Participants needed: 44

Trial details

Phase: Phase 1Age: 19+Biological sex: MaleType: InterventionalSponsor: Addpharma Inc.Updated: Oct 3, 2025

Eligibility criteria

Body weight equal to or greater than 50kg and Body mass index (BMI) between 18.0... [+1]

Participation in another clinical study with an investigational drug within the... [+1]

Status: Not yet recruiting

The Food Effect on PK Characteristics and Safety Profiles of PA-111

Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of PA-111 in healthy subjects.

Participants needed: 40

Trial details

Phase: Phase 1Age: 19+Biological sex: AllType: InterventionalSponsor: Addpharma Inc.Updated: May 16, 2025Locations: 1

Eligibility criteria

Body weight equal to or greater than 50kg (Female 45kg) and Body mass index (BMI... [+1]

Participation in another clinical study with an investigational drug within the... [+1]

Status: Recruiting

A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111A

Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of PA-111 in healthy subjects.

Participants needed: 48

Trial details

Phase: Phase 1Age: 19+Biological sex: AllType: InterventionalSponsor: Addpharma Inc.Updated: Apr 17, 2025Locations: 1

Eligibility criteria

Body weight equal to or greater than 50kg (Female 45kg) and Body mass index (BMI... [+1]

Participation in another clinical study with an investigational drug within the... [+1]

Status: Not yet recruiting

A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-120 and AD-120A

Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-120 in healthy subjects.

Participants needed: 48

Trial details

Phase: Phase 1Age: 19-50Biological sex: AllType: InterventionalSponsor: Addpharma Inc.Updated: Apr 8, 2025Locations: 1

Eligibility criteria

Body weight equal to or greater than 50.0kg and equal to or less than 90.0kg and... [+2]

Patients with trouble performing pH monitor catheter

Status: Recruiting

A Study to Compare PK Characteristics and Safety Profiles Between AD-228B and AD-2284

Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-228B in healthy subjects.

Participants needed: 60

Trial details

Phase: Phase 1Age: 19+Biological sex: AllType: InterventionalSponsor: Addpharma Inc.Updated: Mar 20, 2025Locations: 1

Eligibility criteria

Body weight equal to or greater than 50kg (Female 45kg) and Body mass index (BMI... [+1]

Participation in other clinical study with an investigational drug within the 6... [+1]

Status: Recruiting

A Study to Evaluate the Efficacy and Safety of AD-218

The purpose of this study is to evaluate the efficacy and safety of AD-218

Participants needed: 520

Trial details

Phase: Phase 3Age: 19+Biological sex: AllType: InterventionalSponsor: Addpharma Inc.Updated: Feb 5, 2025Locations: 1

Eligibility criteria

A man or woman over 19 years old. [+1]

History of Fibromyalgia, Myopathy etc (CK ≥ 2 X ULN) [+1]

Status: Not yet recruiting

A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282

The purpose of this study is to evaluate the efficacy and safetyof co-administration of AD-2281 and AD-2282 in patients with Primary Hypercholesterolemia

Participants needed: 110

Trial details

Phase: Phase 3Age: 19+Biological sex: AllType: InterventionalSponsor: Addpharma Inc.Updated: Feb 4, 2025

Eligibility criteria

Signed informed consent [+2]

Patients with Secondary Hypercholesterolemia [+1]

Status: Recruiting

A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B

The purpose of this study is to evaluate the efficacy and safety of co-administration of AD-227A and AD-227B in patients with essential hypertension

Participants needed: 251

Trial details

Phase: Phase 3Age: 19+Biological sex: AllType: InterventionalSponsor: Addpharma Inc.Updated: Feb 4, 2025Locations: 1

Eligibility criteria

Signed informed consent [+2]

Patient with Secondary Hypertension [+1]

Status: Recruiting

A Study to Evaluate the Efficacy and Safety of AD-224

The purpose of this study is to evaluate the efficacy and safety of AD-224

Participants needed: 252

Trial details

Phase: Phase 3Age: 19+Biological sex: AllType: InterventionalSponsor: Addpharma Inc.Updated: Feb 4, 2025Locations: 1

Eligibility criteria

Signed informed consent [+2]

Patient with Secondary Hypertension [+1]